Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ultragenyx Pharmaceutical Q2 EPS $(1.17) Beats $(1.32) Estimate, Sales $166.50M Beat $162.50M Estimate

Author: Benzinga Newsdesk | August 05, 2025 03:01pm
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.32) by 11.36 percent. This is a 23.03 percent increase over losses of $(1.52) per share from the same period last year. The company reported quarterly sales of $166.50 million which beat the analyst consensus estimate of $162.50 million by 2.46 percent. This is a 13.24 percent increase over sales of $147.03 million the same period last year.

Posted In: RARE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist